Leflunopharm

Leflunomide, the active ingredient in Leflunopharm, is an immunomodulator (disease-modifying antirheumatic drug, DMARD) presented as an oral tablet for oral use. It treats rheumatoid arthritis and psoriatic arthritis in adult patients. GNH USA supplies Leflunopharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide acts within the disease-modifying antirheumatic drug class to modify immune‑mediated joint disease. - Rheumatoid arthritis: reduces disease activity, slows joint damage and improves functional ability. - Psoriatic arthritis: alleviates joint inflammation and skin manifestations, helping achieve disease control.

Leflunomide may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Alopecia: reversible hair thinning. - Rash: skin irritation or erythema. - Elevated liver enzymes: mild transaminase rise. - Hypertension: increase in blood pressure readings.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury or failure. - Severe infection: opportunistic infections due to immunosuppression. - Pulmonary toxicity: interstitial lung disease. - Bone‑marrow suppression: pancytopenia or severe anemia. - Stevens‑Johnson syndrome: severe skin reaction. - Teratogenicity: fetal malformations when exposure occurs in pregnancy.

Before initiating therapy, clinicians should assess baseline safety parameters and counsel patients on risk mitigation. - Liver monitoring: check hepatic function before start and periodically thereafter. - Blood pressure: measure regularly and manage hypertension. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Hematology: perform complete blood counts to detect cytopenias. - Drug discontinuation: stop promptly if serious adverse events develop. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Leflunomide can alter the effects of several concomitant medicines.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Methotrexate: additive toxicity, especially hepatic. - Live vaccines: reduced efficacy and potential infection risk.

Moderate Interactions (Monitor Closely): - Azathioprine: enhanced immunosuppression, monitor blood counts. - Cyclosporine: possible increased nephrotoxicity. - Statins: modest increase in statin plasma levels, watch for myopathy.